Philips’ MRCAT solution for prostate cancer treatment planning cleared by FDA

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Royal Philips today announced that it has received 510(k) clearance from the FDA for its magnetic resonance for calculating attenuation (MRCAT) solution, a first among MR-only prostate cancer treatment planning solutions.

Part of the company’s Ingenia MR-RT platform, the newly released MRCAT allows physicians treating prostate cancer patients to adopt a single-modality approach to provide high-quality soft-tissue contrast for target delineation, as well as providing density information for dose calculations.

“MR-only simulation is a continuation of Philips’ commitment to driving image-guided therapy in the market. Where CT solutions have played a leading role in past radiotherapy treatments, MR takes an innovative approach by providing physicians with increased soft-tissue visualization and functional imaging capabilities to help improve treatment plans,” said Lizette Warner, PhD, of Philips North America. “MR-only simulation makes MR more accessible for hospitals and physicians, transforming the way care is delivered and supporting our customers in improving care for oncology patients who require radiotherapy.”

The newly cleared MRCAT MR-only simulation solution has also received CE mark.

Read the full announcement here.